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Summary
Background: According to a recent Portuguese study the prevalence of lifetime consumption of heroin in the global 
population (age range: 15-74 years) is 0.5%. Methadone is the standard pharmacological treatment, while buprenorphine 
has been available since 1999 as an alternative treatment. Nevertheless, no comparative economic evaluation of the cost-
effectiveness of these therapies has been made available. Aim: This study estimates the cost-effectiveness and cost-utility 
of a fixed dose combination of buprenorphine-naloxone (B/N) versus methadone as substitution treatments for opioid 
drug dependence from the Portuguese social perspective. Material and Methods: The comparator for B/N was methadone 
treatment, which is the most common pharmacological therapy and current clinical practice in Portugal. Health gains 
were measured using the number of heroin-free days per year (indicator of effectiveness) and quality-adjusted life years 
(QALYs) associated with each treatment. Estimated costs included acquisition, preparation and transport of medication; 
costs of dispensing and supervision of administration; costs arising from the periodic monitoring of patients and the non-
medical direct costs of crime associated with drug addiction. Results: The B/N combination is associated with an incre-
mental cost-utility ratio of €5,914 per QALY gained. The B/N combination is dominant when the analysis includes costs 
of crime associated with drug addiction. Conclusions: The results suggest that this combination is cost-effective and has 
the potential to generate health gains in the target population at a low cost.
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1. Introduction
Opioid use disorder is a worldwide health prob-
lem with major individual, economic and public 
health consequences [36, 37]. Opioid addiction is 
also related to severe health problems, including an 
increased risk of contracting HIV and/or viral hepa-
titis C and B infections, as a possible consequence of 
intravenous drug use [6]. The European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) es-
timates that there are 1.3 million problematic opioid 
users in Europe, of which about 700,000 received 
medically assisted treatment in 2012 [6]. Recent data 
have shown that in the 15-64 year age range of its 
population, Portugal has one of the lowest prevalence 
rates of drug abuse in Europe, with the exception of 
heroin, which has presented a more regular consump-
tion pattern than several other European countries. 
Among heroin users, almost 40% reported daily use 
and about 30% reported consuming it four or more 
times per week [1-2,6]. Portuguese data from the 
European Drug Report 2014 show that, considering 
the total demand for drug abuse treatment, opioid us-
ers correspond to 70.1% of all entrants and 54.4% of 
first-time entrants [6]. 
Opioid addiction should be considered a dis-
ease that can be successfully treated, especially by 
comparison with other substance use disorders, and 
several effective treatment strategies are currently 
available. Opioid agonist treatment (whether rely-
ing on methadone, buprenorphine or buprenorphine/
naloxone) has become the most common treatment in 
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controlling the effects of illicit drug use [33]. 
Methadone, first used in Portugal in 1978, is a 
full opioid agonist and is currently the most widely 
used pharmacological treatment. However, due to its 
safety profile and compliance requirements, most pa-
tients have a supervised intake, which may be difficult 
to manage, due to the interference of the dispensing 
schedules with other daily activities.
Buprenorphine, an opioid partial agonist, was 
authorized in Portugal in 1999. Buprenorphine pre-
scribed at fixed doses (above 7 mg per day) did not 
differ from methadone in its capacity to retain pa-
tients in treatment and suppress illicit opioid use [25]. 
It has also broadened access to patient care and may 
satisfy unmet needs in the opioid-dependent popula-
tion [21]. The literature has documented the fact that 
methadone and buprenorphine are the most effective 
treatments for patients dependent on heroin [8, 18, 
19, 31]. On the other hand, the risk of misuse and 
diversion to the illicit market associated with metha-
done and buprenorphine has proven to be a difficult 
problem to solve. With the aim of preventing the 
misuse of the drug, a buprenorphine/naloxone (B/N) 
combination (Suboxone®) was developed. The pres-
ence of naloxone, an opioid antagonist, prevents the 
attainment of the desired effects when B/N is injected. 
The B/N combination was approved by the European 
Medicines Agency (EMA) in September 2006 as an 
oral substitution treatment for opioid drug depend-
ence within a framework of medical, social and psy-
chological treatments [34].
In contrast to methadone, which is given free 
of charge to patients in Portugal, formulations of bu-
prenorphine (whether prescribed alone or in combi-
nation with naloxone) are subject to a co-payment of 
63% by patients, which can severely limit access to 
its benefits. 
This study presents a pharmacoeconomic evalu-
ation of the B/N combination in mainland Portugal, 
adding to previous work related to Southern European 
countries [9, 24]. It estimates the cost-effectiveness 
and cost-utility of the B/N combination vs methadone 
from a social perspective, including the costs and 
consequences for all the parties concerned. 
2. Methods
2.1. Model overview
This analysis is based on a cost-utility model 
created by the York Health Economics Consortium 
[38]. The model used data reported by Marino and 
Lazzaro [23], because of the lack of information pub-
lished in Portugal on resource consumption in the 
treatment of opioid dependence. The study used by 
Marino and Lazzaro had been carried out by the De-
partment of Addictions of the Local Health Authority 
in Varese, Italy. The study included 512 patients on 
maintenance therapy with methadone, and 211 with 
the B/N combination.
The timeframe for the economic evaluation was 
one year. In this way the study did not include dis-
count rates that might have been subject to possible 
exceptions to be presented later on.
2.2. Treatment comparator 
For the B/N combination an average daily dose 
of 8 mg was considered. Methadone was selected as 
comparator, since, besides being the most common 
therapeutic therapy, it also reflects current clinical 
practice according to the National Drug and Addic-
tion Institute (Instituto da Droga e Toxicodependên-
cia - IDT). The standard programme defined by IDT 
targets abstinence from heroin and other psychoactive 
substances, and is part of a broader programme of 
medical, psychological and social intervention [12]. 
According to IDT, the average daily dose of metha-
done is 75 mg. 
2.3. Effectiveness and Quality of Life Inputs
The measure of effectiveness used was the 
number of heroin-free days, estimated from the per-
centage of time in which urine tests undertaken by pa-
tients revealed no illegal opioids [23]. Utilities associ-
ated to heroin-free days and heroin-using days were 
used as a measure of health-related quality of life. A 
conservative assumption whereby possible effects on 
quality of life related to the convenience, autonomy 
or adverse effects associated with the different treat-
ments was ignored. 
Utilities related to heroin-free day and heroin-
using day were computed by adjusting values from 
the literature. The utility of a heroin-free day was cal-
culated from the study of Harris et al. [13]. In this 
study patients who were on methadone had a utility 
value of 0.59 (CI: 95% from 0.54 to 0.65) and on bu-
prenorphine of 0.62 (CI 95% 0.56 to 0.68). Conserva-
tively, it was considered that the utility deriving from 
a heroin-free day was independent of treatment, so 
that the average of both values for utility (0.605) was 
used in the model.
Given that heroin addiction is associated with 
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multiple negative health consequences [7, 26, 28-30], 
the quality of life of a heroin-use day was calculated 
by adjusting estimates from Barnett et al. [3]. In that 
study, the utility for patients not using heroin was 0.9 
and for those using heroin was 0.8. The absolute val-
ues are debatable, but it was assumed that the relative 
values were accurate. Thus, the utility per heroin-free 
day (0.605) was multiplied by the ratio between the 
two utility values (0.8/ 0.9), to reach the value 0.538 
for a heroin-use day [23].
The number of days spent in each state was esti-
mated for both treatments. According to Marino and 
Lazzaro the proportion of heroin-free days was 0.677 
with methadone and 0.779 with the B/N combina-
tion [23]. These annual estimates correspond to 247 
heroin-free days with methadone and 284 heroin-free 
days with B/N. 
The overall value for utility was calculated by 
aggregating total days and their respective utility 
value. According to this methodology, improvements 
in quality of life can be achieved by increasing the 
number of heroin-free days. 
Even though the time horizon of the analysis 
was restricted to one year, it was still necessary to in-
clude the effect of mortality on treatment. In order to 
estimate the QALYs lost by premature deaths attrib-
utable to treatment, the life expectancy of an average 
patient was calculated. The average mortality rate for 
opioid addicts is 1.84% according to Oppenheimer et 
al. [28]. By combining these data with the mortality 
rates provided by the Portuguese National Statistics 
Institute (INE) for 2009-2011, a composite mortality 
table was estimated for the opioid-dependent popula-
tion [17]. The mean patient age was 37.7 years [23]. 
The mean estimated life expectancy at 38, adjusted 
for quality of life related to opioid dependence and 
discounted at a 5% rate, was 4.56 years. This is the 
only situation where a discount rate has been used in 
this study. The value of 5% is a mandatory rate ac-
cording to the Portuguese Health Technology assess-
ment guidelines [15].
 These are the QALYs lost when there is a pre-
mature death attributable to treatment. According to 
Gibson et al., the mortality rate for methadone was 
2.75 (per 1,000 patients in treatment) [10]. Informa-
tion for the B/N combination was not available, so 
the rate for buprenorphine was used (0.02 per 1,000 
patients in treatment). The QALYs lost due to annual 
premature mortality related to treatment can be cal-
culated by multiplying the 4.56 QALYs by the prob-
abilities of death according to each type of treatment. 
Overall, annual estimated QALYs for the treat-
ment with the B/N combination were 0.590 (whether 
with or without mortality), as against 0.583 (without 
mortality) and 0.570 (with mortality) for the treat-
ment with methadone.
2.4. Costs data 
2.4.1. Drug treatment of heroin addiction
Cost estimates for the B/N combination were 
based on data from the National Authority for Medi-
cines and Health Products (INFARMED) [14]. An av-
erage daily dose of 8 mg per patient was considered 
for the B/N combination as established by the World 
Health Organization [36]. The estimated cost per year 
per patient was €1,011. This cost is partly paid by the 
patients themselves.
Cost estimates for methadone were based on the 
information provided by IDT, since its acquisition, 
production and distribution occurs completely within 
public sector institutions. As stated above, the aver-
age daily dose of methadone is 75 mg and it is avail-
able in three different formats: oral solution, tablets 
of 10 mg and of 40 mg. In 2012 IDT acquired 540 kg 
of powder for oral solution (€161,028), tablets of 10 
mg (€51,348) and tablets of 40 mg (€65,438). 
Numbers of patients in treatment with metha-
done (oral solution and tablets) were based on the 
2011 IDT report [16]. According to this source, as of 
December 31st of that year, 16,561 individuals were 
enrolled in methadone treatment in mainland Portu-
gal. As this value corresponds to a likely estimate of 
the average number of individuals under treatment at 
any given moment, it was considered as the number 
of methadone treatment years provided by IDT. 
Part of the methadone acquired by IDT is sent to 
the Madeira and Azores islands. To estimate the ad-
ditional treatments provided in these islands, the ratio 
between treatments and population in the islands and 
those in mainland Portugal was calculated, resulting 
in 848 additional years of treatment. Estimates of 
years of treatment with methadone took into account 
the amount sent to the islands, the number of years of 
treatment in the format of methadone tablets (1,065) 
and assumptions about powder and tablet losses. The 
final results for mainland Portugal, the object of this 
study, were a total of 15,496 treatment years with oral 
solution. 
Cost estimate for methadone included prepara-
tion of the oral solution by the Military Laboratory, 
with a unit cost of €4 per litre container, provided by 
IDT. An estimate was also made for the distribution to 
each treatment centre, based on: the number of cen-
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tres; mean distance of each Centre from Regional Of-
fices; and mean cost per kilometer using Portuguese 
legislation (Decree-Law 137/2010 of 28 December). 
An average of 12 minutes for the preparation and dis-
pensing of each methadone dose was considered for 
the purpose of estimating nursing labour costs (Or-
dinance 1553D December 31, 2008). This estimate 
took into account administrative and general costs 
(including energy, and security), too. 
2.4.2. Health- and social care-related costs
Health- and social care-related costs included 
physicians’ visits, psychotherapeutic evaluations and 
interventions, toxicology drug tests and visits by so-
cial workers. 
The resource consumption pattern was based on 
Marino and Lazzaro study [23]. Resource unit costs 
were obtained from Portuguese legislation (Ordi-
nance 839-A/2009). For patients on methadone treat-
ment, costs associated with the administration of vac-
cines and other medicines were included. For the B/N 
combination the dispensing cost is included in the 
overall medication cost, as this medicine is available 
in a community pharmacy context. Toxicology drug 
test unit costs (covering urine, breath and saliva) were 
estimated on the basis of information provided by the 
IDT. The estimated average cost per patient per year 
was €22.91 (Table 1).
2.5. Sensitivity analysis
The robustness of the results was evaluated with-
out the component of premature mortality associated 
with opioid substitution therapy. 
The impact on the results of opioid addiction 
crime-related costs was evaluated, too. The patterns 
of criminal activity for a period of one year associ-
ated with each treatment were taken from Taylor et 
al. [35]. The adjustment from British to Portuguese 
costs assumed the proportionality to the gross domes-
tic product (GDP) per capita in 2011 for both coun-
tries, using market exchange rates as established by 
Eurostat [32].
The costs related to violations of the ‘Illicit Sub-
stances Law’ were estimated on the basis of data from 
the Portuguese study "Droga e Propinas – Avaliações 
de impacto legislativo” [11]. According to this source, 
public expenditure for incarceration based on these 
violations reached 35 million Euros in 2010. Costs 
of courts associated with criminal offenses related to 
the laws on illicit substances were estimated at about 
3 million Euros in 2010. Lastly, the estimated costs 
associated with law enforcement against violations 
of the ‘Illicit Substances Law’ were approximately 
Table 1. Health- and social care-related costs
Resources B/N combination (€ /patient/year)
Methadone
(€ /patient/year)
Psychiatric follow-up visit 252.45 340.58
Interview for psychological follow-up 216.68 207.16
Toxicology drug tests (urine, breath and saliva) 188.20 188.90
Medication and vaccine administrations 26.00 641.92
Individual psychotherapy 22.62 28.53
Family psychoeducational group sessions 0.24 1.68
Psychological tests 32.18 14.36
Social worker visit 1.38 3.21
Drug Monitoring visit 328.44 430.97
B/N: Buprenorphine and naloxone. 
Table 2. Costs of crime
Type of crime B/N combination (€ /patient/year)
Methadone
(€ /patient/year)
Home robbery € - € 208.0
Non-car robbery € 213.2 € 3,087.4
Car robbery € - € 131.6
Other crimes related to property € 29.1 € 27.6
Violations of law on illicit substances € 27.5 € 41.3
B/N: Buprenorphine and naloxone.
- 47 -
M. Gouveia et al.: Economic evaluation of Suboxone® for substitution treatment of opioid drug dependence in Portugal
Ratio (ICUR). Despite these results, the level of the 
incremental cost-utility ratio remains below standard 
thresholds, with the outcome that the B/N combina-
tion is still cost-effective.
3.2.2. Inclusion of costs of crime 
The baseline scenario did not include the crime-
related costs. If these are included in the analysis, 
the results change. In this case the B/N combination 
acquires the status of the dominant intervention, be-
cause of lower costs and higher QALY. More specifi-
cally, treatment with B/N was associated with cost 
savings of €3,112 and a figure of 0.02 for incremental 
QALY (Table 5). If the costs of crime and the absence 
of premature deaths are considered jointly, the domi-
nance of the B/N combination is preserved.
4. Discussion
Given the limitations of the study, these esti-
mates followed a conservative approach. First, indi-
rect costs were not included in the analysis. Accord-
ing to the 2011 IDT Report, 93.9% of drug users 
were 20 to 54 years old. From a societal perspective, 
therefore, values linked with changes in employment 
rates would have to rank as important parameters in-
fluencing overall cost-effectiveness. Data from the 
EQUATOR study [4] showed that employment status 
varied according to treatment. In that study a higher 
proportion of patients receiving mono-buprenorphine 
or the B/N combination were employed compared 
to patients receiving methadone or slow-release oral 
26 million Euros in 2010. For 2010, these costs to-
talled 64 million Euros, arising from 13,500 offences, 
which corresponds to an average cost of €4,741 per 
offence. Table 2 shows the annual costs per patient, 
with variations generated by treatment-related differ-
ences in the frequencies of crimes.
3. Results
3.1. Baseline scenario
Table 3 summarizes the average annual costs per 
patient for the two types of treatment. 
In Table 4 baseline incremental cost-effective-
ness and cost-utility ratios per patient in the case of 
treatments based on the B/N combination are com-
pared with those where methadone therapy was used. 
Treatment with the B/N combination was more costly 
(€2,079 vs. €1,965) and more effective (0.59 vs. 0.57 
QALY) compared with methadone treatment. Over-
all, B/N treatment exhibits an incremental cost per 
QALY gain of €5,914 and an incremental cost per 
heroin-free day of €3.1. 
3.2 Sensitivity Analyses
3.2.1. No premature death 
In this subsection the advantage of the B/N com-
bination in having lower treatment-related mortality 
has not been included in the analysis. Results in Table 
5 show that premature mortality has a non-negligible 
impact in contributing to the Incremental Cost-Utility 
Table 3. Average annual cost of treatment for opiate dependence





Drug treatment of heroin addiction 1,011.13 107.70 903.43
Health- and social care-related costs 1,068.18 1,857.31 -789.13
Total cost 2,079.31 1,965.01 114.30
B/N: Buprenorphine and naloxone.





Total Costs €2,079.3 €1,965.0 €114.3
Total QALYs 0.5901 0.5707 0.0193
Heroin-free days 284 247 37
Incremental Ratios: 
ICUR (€/QALY) €5,914.1*
ICER (€/Heroin-free day) €3.06*
B/N: Buprenorphine and naloxone. *Exact values of ratios reported.
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Patients treated with methadone could present char-
acteristics different from those of patients treated 
with B/N, so biasing the results. On the other hand, 
Marino and Lazzaro [22] state explicitly that there 
was no heterogeneity or sample selection bias be-
tween treatment groups, so leading one to expect that 
the potential for bias in the cost-effectiveness results 
was minimal.
Another limitation of the analysis is that the 
utility measures only reflect heroin-free days. There 
are other ways by which different treatments lead to 
differences in the quality of life, such as effects on 
mood, side-effects and the burden associated with the 
dispensing schedules. It is likely that this limitation 
leads to an underestimate of the cost-effectiveness of 
using B/N. 
The results are in line with those available in the 
international literature – in particular, studies on the 
cost-effectiveness of B/N in Italy [22-23], Greece [9] 
and Australia [5]. All these studies have shown that 
B/N is cost-effective when compared to methadone, 
so indicating that the economic advantages of B/N 
appear to have the some robustness across different 
health systems.
5. Conclusions 
Results of the economic evaluation of the B/N 
combination for opioid substitution treatment versus 
methadone, in Portugal, showed an incremental cost 
of €5,914 per QALY and €3.06 per heroin-free day. 
If the analysis is broadened to include the costs of 
crime associated with drug addiction, these estimates 
improve so much that the B/N combination becomes 
dominant. Overall, the results suggest that the B/N 
combination is cost-effective and has the potential to 
generate substantial health gains at low costs for the 
Portuguese health system. This implies that improv-
morphine. According to the authors of that study, dai-
ly clinical attendance and supervised dosing may act 
as barriers to getting and keeping a job [4].
It seemed reasonable to assume that treatment 
with the B/N combination would be beneficial com-
pared with methadone treatment. However, no reli-
able data on Portuguese patients’ participation in the 
labour market by type of treatment were available.
The second limitation of this study relates to the 
role of the Military Laboratory in the processing of 
methadone. The costs used in the analysis may be un-
derestimated, as the fixed price charged by the Mili-
tary Laboratory (€4 per bottle) includes storage, man-
ufacturing, primary packaging, transport and security 
services. Considering the set of services provided – in 
particular transport and security – this value seems to 
be, implicitly, heavily subsidized. 
In addition, it should be noted that, given the ab-
sence of reliable information, some important issues 
could not be quantified. The role of opioid substitu-
tion treatment in reducing the transmission of infec-
tious diseases (hepatitis B, hepatitis C and HIV) was 
not taken into account. This is of special importance 
in Portugal due to the high prevalence of these dis-
eases among injecting drug users. The prevalence of 
HIV in this population is 5.3 per million individuals 
(well above the European Union average of 3.5) [6], 
of hepatitis C antibodies (anti-HCV) is 83.1% and of 
hepatitis B core antibodies (anti-HBc) is 53.7% [27]. 
According to a recent meta-analysis, treatment 
with methadone was associated with health gains re-
lated to these infectious diseases [20]. Thus it is plau-
sible that treatment with the B/N combination could 
generate further health gains by increasing compli-
ance with the therapy prescribed and, therefore, by 
reducing injection drug use.
One further limitation of this study comes from 
the use of data reported by Marino and Lazzaro [23]. 






Total Cost €2,079.3 €1,965.0 €114.3
QALYs 0.5902 0.5833 0.0069
ICUR (€/QALY) €16,604*
Inclusion of costs of crime 
Total Cost €2,349.2 €5,461.0 €- 3,112
QALYs 0.5901 0.5707 0.0193
ICUR (€/QALY) Dominant
B/N: Buprenorphine and naloxone. *Exact values of ratios reported.
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ing access is desirable, particularly when it is con-
sidered that methadone treatment is free of charge to 
patients in Portugal, whereas treatment with the B/N 
combination is not.
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